文献速递心律失常

eMERGE-III测序研究中的心律失常变异关联与重新分类

Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study.
PubMed 文献 · Circulation · 2021-12-21

0.6%携带心律失常基因P/LP变异,其电子健康记录心律失常表型负荷显著高于非携带者;54例结果返回者中19例诊断遗传性心律失常综合征,12例仅在结果返回后确诊;50个VUS经体外功能实验后11个重新分类。

要点

  • 无心律失常遗传检测指征人群中0.6%携带心律失常基因P/LP变异。
  • P/LP携带者电子健康记录心律失常表型负荷显著高于非携带者。
  • 54例结果返回者中12例诊断仅在结果返回后确立。

核心结论

  • 在无心律失常遗传检测指征的大人群中,基因组测序可识别表型阳性的先天性心律失常综合征致病基因变异携带者。
  • 整合基因组筛查、电子健康记录表型和体外功能研究可评估心律失常基因罕见变异的疾病风险。

研究设计与样本

  • 对109个孟德尔疾病基因测序,其中10个与心律失常综合征相关。
  • 对携带者进行电子健康记录表型评估和随访临床检查。
  • 选取50个VUS在HEK293细胞中进行自动化电生理体外功能实验。

主要发现

  • 120名参与者(0.6%)携带心律失常基因P/LP变异。
  • 心律失常P/LP携带者的电子健康记录心律失常表型负荷显著高于非携带者。
  • 54名参与者返回了变异结果,其中19例诊断为遗传性心律失常综合征(主要为长QT综合征)。
  • 19例诊断中12例仅在变异结果返回后确立(0.05%)。
  • 50个VUS经体外功能评估后11个重新分类:3个为可能良性,8个为P/LP。

关键数值与推荐

  • 109个基因中P/LP变异携带者占3.0%(既往报道)。
  • 54例结果返回者中19例诊断遗传性心律失常综合征,12例诊断仅在结果返回后确立(0.05%)。
  • 50个VUS中11个重新分类:3个可能良性,8个P/LP。

临床怎么用

  • 对无心律失常遗传检测指征人群,基因组测序可发现表型阳性的心律失常基因P/LP携带者。
  • 电子健康记录表型结合体外功能实验有助于VUS重新分类和风险分层。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sequencing Mendelian arrhythmia genes in individuals without an indication for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) variants. However, the extent to which these variants are associated with clinically meaningful phenotypes before or after return of variant results is unclear. In addition, the majority of discovered variants are currently classified as variants of uncertain significance, limiting clinical actionability. METHODS: The eMERGE-III study (Electronic Medical Records and Genomics Phase III) is a multicenter prospective cohort that included 21 846 participants without previous indication for cardiac genetic testing. Participants were sequenced for 109 Mendelian disease genes, including 10 linked to arrhythmia syndromes. Variant carriers were assessed with electronic health record-derived phenotypes and follow-up clinical examination. Selected variants of uncertain significance (n=50) were characterized in vitro with automated electrophysiology experiments in HEK293 cells. RESULTS: As previously reported, 3.0% of participants had P/LP variants in the 109 genes. Herein, we report 120 participants (0.6%) with P/LP arrhythmia variants. Compared with noncarriers, arrhythmia P/LP carriers had a significantly higher burden of arrhythmia phenotypes in their electronic health records. Fifty-four participants had variant results returned. Nineteen of these 54 participants had inherited arrhythmia syndrome diagnoses (primarily long-QT syndrome), and 12 of these 19 diagnoses were made only after variant results were returned (0.05%). After in vitro functional evaluation of 50 variants of uncertain significance, we reclassified 11 variants: 3 to likely benign and 8 to P/LP. CONCLUSIONS: Genome sequencing in a large population without indication for arrhythmia genetic testing identified phenotype-positive carriers of variants in congenital arrhythmia syndrome disease genes. As the genomes of large numbers of people are sequenced, the disease risk from rare variants in arrhythmia genes can be assessed by integrating genomic screening, electronic health record phenotypes, and in vitro functional studies. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier; NCT03394859.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Glazer AM, Davogustto G, Shaffer CM, et al. Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study. Circulation. 2021. PMID: 34930020. doi:10.1161/CIRCULATIONAHA.121.055562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。